NL300421I2 - Humane monoklonale anti-TNFalfa antilichamen. - Google Patents

Humane monoklonale anti-TNFalfa antilichamen.

Info

Publication number
NL300421I2
NL300421I2 NL300421C NL300421C NL300421I2 NL 300421 I2 NL300421 I2 NL 300421I2 NL 300421 C NL300421 C NL 300421C NL 300421 C NL300421 C NL 300421C NL 300421 I2 NL300421 I2 NL 300421I2
Authority
NL
Netherlands
Prior art keywords
tnf alpha
human monoclonal
human
antibodies
tnfalfa
Prior art date
Application number
NL300421C
Other languages
English (en)
Other versions
NL300421I1 (nl
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26701860&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300421(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of NL300421I1 publication Critical patent/NL300421I1/nl
Publication of NL300421I2 publication Critical patent/NL300421I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
NL300421C 1993-03-05 2009-10-20 Humane monoklonale anti-TNFalfa antilichamen. NL300421I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2695793A 1993-03-05 1993-03-05
US14506093A 1993-10-29 1993-10-29

Publications (2)

Publication Number Publication Date
NL300421I1 NL300421I1 (nl) 2010-01-04
NL300421I2 true NL300421I2 (nl) 2010-04-01

Family

ID=26701860

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300421C NL300421I2 (nl) 1993-03-05 2009-10-20 Humane monoklonale anti-TNFalfa antilichamen.

Country Status (11)

Country Link
US (1) US5654407A (nl)
EP (1) EP0614984B2 (nl)
JP (2) JP4225519B2 (nl)
AT (1) ATE204299T1 (nl)
CA (1) CA2116888C (nl)
DE (2) DE122009000074I1 (nl)
DK (1) DK0614984T4 (nl)
ES (1) ES2159529T5 (nl)
LU (1) LU91661I2 (nl)
NL (1) NL300421I2 (nl)
PT (1) PT614984E (nl)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE10399036I1 (de) 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU2012261708B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2013257402B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2013203420B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
ATE549918T1 (de) * 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6624295B1 (en) * 1998-08-28 2003-09-23 Genentech, Inc. Human anti-factor IX/IXa antibodies
DE60045240D1 (de) * 1999-03-02 2010-12-30 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DK1237575T3 (da) * 1999-12-14 2008-12-08 Genentech Inc TNF-alfa-antagonist og LFA-1-antagonist til behandling af rheumatoid arthritis
US20090081234A1 (en) * 2000-08-07 2009-03-26 George Heavner Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN102755646A (zh) * 2002-07-19 2012-10-31 艾博特生物技术有限公司 TNF α相关疾病的治疗
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CN100434440C (zh) 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US20040185047A1 (en) * 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN101142320A (zh) * 2004-07-12 2008-03-12 拉帕波特家族医学研究院 检测多态性蛋白质的表型的方法
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
DE602005026571D1 (de) * 2004-12-29 2011-04-07 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
PT2390267E (pt) 2005-06-07 2013-07-16 Esbatech A Novartis Co Llc Anticorpos estáveis e solúveis que inibem tnf(alfa)
ATE470151T1 (de) * 2005-08-02 2010-06-15 Xbiotech Inc Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP1937815B1 (en) * 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
JP4861019B2 (ja) * 2006-01-31 2012-01-25 独立行政法人科学技術振興機構 ヒトＴＮＦ−αに対する抗体酵素およびその利用
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ATE528319T1 (de) * 2006-05-22 2011-10-15 Xbiotech Inc Krebsbehandlung mit anti-il-1-antikörpern
MX2009007570A (es) * 2007-01-16 2009-07-22 Abbott Lab Metodos para tratar la psoriasis.
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
JP5759722B2 (ja) 2007-08-28 2015-08-05 アッヴィ バイオテクノロジー リミテッド アダリムマブの結合蛋白質を含む組成物及び方法
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
WO2009097095A2 (en) * 2008-01-28 2009-08-06 The Regents Of The University Of California Methods for treating hematopoietic malignancies
AU2009224690B2 (en) * 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
CA2718184A1 (en) * 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
HUE028962T2 (en) * 2008-03-13 2017-01-30 Biotest Ag Active ingredient for treating disease
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
PL2285409T3 (pl) * 2008-05-30 2016-10-31 Przeciwciała il-1 alfa
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク，インコーポレイテッドＸｂｉｏｔｅｃｈ，Ｉｎｃ． 病原性単球の標的化
RU2531548C2 (ru) * 2008-09-29 2014-10-20 Биотест Аг Композиция для лечения заболевания
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
KR20210128021A (ko) 2010-08-23 2021-10-25 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
WO2012103260A2 (en) * 2011-01-25 2012-08-02 Cdi Laboratories High-throughput methods to produce, validate and characterize mmabs
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
JP2015512877A (ja) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10081673B2 (en) 2013-03-14 2018-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
HUE051013T2 (hu) 2015-01-20 2021-01-28 Igm Biosciences Inc Tumor nekrózis faktor (TNF) szupercsalád receptor kötõ molekulák és ezek alkalmazása
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CN107903323B (zh) * 2017-11-15 2020-04-17 中国药科大学 抗hTNF-α全人源抗体及其用途
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
US20230340086A1 (en) 2019-06-19 2023-10-26 Christopher Roland Oelkrug Antibody-mediated neutralization of beta-lactamases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000607A1 (en) † 1987-07-09 1989-01-26 The United States Of America, As Represented By Th Preparation of human monoclonal antibodies of selected specificity and isotypes
WO1991002756A1 (en) * 1989-08-16 1991-03-07 Cetus Corporation Prohormone cleavage site blocking antibody
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB9109645D0 (en) † 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DE69321909T2 (de) † 1992-08-28 1999-04-01 Bayer Ag Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden

Also Published As

Publication number Publication date
ATE204299T1 (de) 2001-09-15
DE69427928T2 (de) 2001-11-29
DE69427928D1 (de) 2001-09-20
DE69427928T3 (de) 2012-05-10
EP0614984B1 (en) 2001-08-16
ES2159529T3 (es) 2001-10-16
EP0614984B2 (en) 2010-11-03
PT614984E (pt) 2001-12-28
JPH06319587A (ja) 1994-11-22
CA2116888C (en) 2003-08-12
DK0614984T3 (da) 2001-11-05
CA2116888A1 (en) 1994-09-06
LU91661I2 (fr) 2010-05-10
JP4225519B2 (ja) 2009-02-18
US5654407A (en) 1997-08-05
EP0614984A3 (en) 1995-05-24
NL300421I1 (nl) 2010-01-04
JP2009046487A (ja) 2009-03-05
EP0614984A2 (en) 1994-09-14
ES2159529T5 (es) 2011-03-09
DK0614984T4 (da) 2010-12-20
DE122009000074I1 (de) 2011-12-01

Similar Documents

Publication Publication Date Title
DK0614984T3 (da) Humane monoklonale anti-TNFalfa-antistoffer
IL83113A (en) Bifunctional antibodies having antigen specificity for fc receptor and for an epitope of a target cell
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
DK0848755T3 (da) VEGF relateret protein
KR890701632A (ko) 사람 인터루킨-4에 대한 모노클로날 항체 및 이를 생성하는 하이브리도마
ZA874558B (en) Monoclonal antibodies to unreduced,nonenzymatically-glycated proteins
KR880700823A (ko) 사이토메갈로 바이러스에 대한 사람.모노클로날 항체와 그 제조방법
ATE375802T1 (de) Ccr5 antikörper pa14
Nasiri et al. Production and purification of polyclonal antibody against F (ab') 2 fragment of human immunoglobulin G
DE59410219D1 (de) Monoklonale antikörper gegen ck-mb
Ohlson et al. High-performance liquid affinity chromatographic separation of mouse monoclonal antibodies with protein A silica
Johnston et al. Studies of human anti-IgM anti-IgG cryoglobulins. I. Patterns of reactivity with autologous and isologous human IgG and its subunits.
Sugiura et al. Production of monoclonal antibodies to six isotypes of horse immunoglobulin
Bird et al. Analysis of the expression and secretion of isotypes of sheep B cell immunoglobulins with a panel of isotype-specific monoclonal antibodies
SE8201226L (sv) Antikroppar mot proteiner
Würzner et al. Determination of the epitope specificities of monoclonal antibodies using unprocessed supernatants of hybridoma cultures
Storch et al. A new and rapid method for immunoglobulin class and subclass determination of mouse monoclonal antibodies using a solid-phase immunoradiometric assay
Takeo et al. Studies on heterogeneity of anti-DNP antibody by means of two-dimensional affinity electrophoresis
KR900700135A (ko) 광견병 비루스 세포를 특이적으로 인지하는 사람 모노클로날 항체, 이의 생성세포, 그 항체를 함유하는 제제 및 이들의 제조방법
Tanaka et al. Murine monoclonal anti-Ba antibody that enhances haemolytic activity of factor B.
Jones et al. The isotype and specificity of antiglobulins in BALB/c mice.
JPH04271795A (ja) インターロイキン５の微量定量
RU2021139258A (ru) Dll3-нацеливающие антитела и их применения
Nilson The bacterial cell wall molecules protein G and protein L: Characterization and use of their immunoglobulin binding properties.
Steinitz et al. Separation of rare cell subpopulations with the aid of biotin-labelled ligands